For: | Wang LM, Zhao P, Sun XQ, Yan F, Guo Q. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report. World J Clin Cases 2023; 11(22): 5322-5328 [PMID: 37621597 DOI: 10.12998/wjcc.v11.i22.5322] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v11/i22/5322.htm |
Number | Citing Articles |
1 |
Yinyin Xue, Wen Li, Kaili Huang, Qinghua Zhou, Qiang Wu. Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1602654
|
2 |
Kazuki Ohta, Naoki Haratake, Shinkichi Takamori, Yuta Abe, Eika Kudo, Takahiro Sato, Kosuke Kamada, Daiki Noda, Miyuki Abe, Yohei Takumi, Michiyo Miyawaki, Tsutomu Daa, Kenji Sugio, Atsushi Osoegawa. Pathological Complete Response in Locally Advanced <i>ALK</i> Fusion Gene–Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review. Surgical Case Reports 2025; 11(1): n/a doi: 10.70352/scrj.cr.25-0238
|
3 |
|
4 |
Diego Luigi Cortinovis, Alessandro Leonetti, Alessandro Morabito, Luca Sala, Marcello Tiseo. Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges. Cancers 2024; 16(14): 2610 doi: 10.3390/cancers16142610
|